Zotarolimus
| CAS No.: 221877-54-9 | Request for quotation |  |
|
Zotarolimus, tetrazole-containing macrocyclic immunosuppressant, known as ABT-578, is a noval analogue of rapamycin (sirolimus) that was designed to have a shorter in vivo half-life than rapamycin. Zotarolimus was not genotoxic in the in vitro bacterial reverse mutation assay, the human peripheral lymphocyte chromosomal aberration assay, or the in vivo mouse micronucleus assay. |
|||
Zotarolimus Specification (Factory standard)
| Appearance | White crystalline powder | Standard Packing | 10g/bag or per customer request | |
| Purity (HPLC) | > 98% | Inventory | Normally we have Zotarolimus in stock | |
| Solubility | Soluble in ethanol, methanol, DMF or DMSO. Limited water solubility. | |||
| Heavy metal | < 20 ppm | Zotarolimus physical parameters | ||
| Total impurity (HPLC) | < 2% | CAS No: | 221877-54-9 | |
| Water | < 3% | Formula | C52H79N5O12 | |
| Isomer | < 10% | Molecular Weight | 966.2 | |
| Synonym | 42-(1-Tetrazolyl)rapamycin; A179578; ABT578; Endeavor; Resolute; ABT-578 | |||
| Structure |  |
|||
| Certificate of Analysis | Zotarolimus COA | |||
| Literature | Zotarolimus literature | |||
| MSDS | Zotarolimus MSDS | |||
| References: | ||||
| 1. | Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens. Burke S.E. et al. US Patent 7,357,942, 2008. | |||
| 2. | Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression Chen Y.W. et al. J. Cardiovasc. Pharmacol. 2007, 49, 228. | |||
| 3. | ||||
| 4. | ||||
| . | ||||
Copyright © 2014. All Rights Reserved |
||||